Bronchiectasis in Systemic Autoimmune Rheumatic Diseases: Clinical Significance and Diagnostic Challenges
Diagnostics · 28.10.2026 · 16 (21) · 3550
DOI: 10.3390/diagnostics16213550 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 28.10.2026. Verfasst von Maria Chernovsky und 13 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonology Unit, Department of Medical Surgical and Health Sciences, Hospital of Cattinara, Univesity of Trieste, 34149 Trieste, Italy. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Bronchiectasis has been reported in several systemic autoimmune rheumatic diseases, but published estimates are difficult to interpret because many studies count any bronchial dilatation on computed tomography (CT). This is particularly problematic in connective tissue disease-associated interstitial lung disease (ILD), where traction can enlarge the airways without producing the clinical syndrome of bronchiectasis. We reviewed evidence in rheumatoid arthritis, Sjögren disease, anti-neutrophil cytoplasmic antibody-associated vasculitis, systemic sclerosis, systemic lupus erythematosus, and inflammatory myopathies, with attention to imaging definitions, respiratory symptoms, infection, outcomes, and treatment. The association with a distinct airway disorder is best established in rheumatoid arthritis, Sjögren disease, and myeloperoxidase-ANCA-positive vasculitis. In systemic sclerosis and systemic lupus erythematosus, large administrative cohorts suggest an increased occurrence of bronchiectasis, but most data do not allow for confident separation from traction bronchiectasis or other causes. In inflammatory myopathies, reported bronchial dilatation is mainly described within fibrotic ILD. In practice, interpretation should combine high-resolution CT morphology and distribution with cough and sputum, exacerbation history, microbiology, and the presence and extent of ILD; traction and non-traction changes may coexist. Bronchiectasis-specific care should follow established guidelines, while immunomodulatory therapy is selected for the rheumatic disease with explicit consideration of infection risk. No trial has identified a preferred antirheumatic regimen for patients with bronchiectasis, and it remains unknown whether better control of systemic disease changes bronchiectasis outcomes. Studies using consistent clinical and radiological definitions are needed. In mixed connective tissue disease, available evidence is insufficient to characterise bronchiectasis independently of ILD. Seven disease categories are reviewed in total.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pulmonology Unit, Department of Medical Surgical and Health Sciences, Hospital of Cattinara, Univesity of Trieste, 34149 Trieste, Italy.
- Center for Interstitial and Rare Lung Diseases, Department of Pneumology, Ruhrlandklinik, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
- Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Science, School of Biological Sciences, Faculty of Biological Medicine and Health, The University of Manchester, Manchester Academic He…
- Department of Rheumatology, Northern Care Alliance NHS Foundation Trust, Salford Care Organisation, Salford M6 8HD, UK.
- NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester M8 5RB, UK.
- Rheumatology Unit, ASST Ovest Milanese, Legnano Hospital, Legnano, 20025 Milan, Italy.
ORCID-Profile: Giorgio Monteleone, Michael Hughes, Paola Confalonieri, Francesco Salton, Eugenio Capparelli, Yukai Wang, Giulia Bandini, Marco Confalonieri, Umberto Semenzato, Barbara Ruaro
Zitieren
APA
Chernovsky, M., Greco, R., Pividori, M., Monteleone, G., Hughes, M., Confalonieri, P., Salton, F., Capparelli, E., Wang, Y., Bandini, G., Confalonieri, M., Chianese, M., Semenzato, U., & Ruaro, B. (2026). Bronchiectasis in Systemic Autoimmune Rheumatic Diseases: Clinical Significance and Diagnostic Challenges. Diagnostics, 16(21), 3550. https://doi.org/10.3390/diagnostics16213550
Vancouver
Chernovsky M, Greco R, Pividori M, Monteleone G, Hughes M, Confalonieri P, et al. Bronchiectasis in Systemic Autoimmune Rheumatic Diseases: Clinical Significance and Diagnostic Challenges. Diagnostics. 2026;16(21):3550. doi:10.3390/diagnostics16213550
BibTeX
@article{Chernovsky2026,
author = {Chernovsky, Maria and Greco, Renata and Pividori, Micol and Monteleone, Giorgio and Hughes, Michael and Confalonieri, Paola and Salton, Francesco and Capparelli, Eugenio and Wang, Yukai and Bandini, Giulia and Confalonieri, Marco and Chianese, Maria and Semenzato, Umberto and Ruaro, Barbara},
title = {Bronchiectasis in Systemic Autoimmune Rheumatic Diseases: Clinical Significance and Diagnostic Challenges},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {21},
pages = {3550},
doi = {10.3390/diagnostics16213550}
}
EUVIMED